IPS-based CAR-T

IPS-based CAR-T is an investigational cell therapy being developed by Shenzhen Innovation Immunotechnology for the treatment of solid tumors. The therapy utilizes induced pluripotent stem cells (iPSCs) as a starting material, which are genetically engineered to express a chimeric antigen receptor (CAR) and then differentiated into functional T cells. This approach aims to create an "off-the-shelf" (allogeneic) cell product, potentially overcoming the limitations of autologous CAR-T therapies, such as high manufacturing costs and variability in patient-derived cell quality. The program is currently in the preclinical stage of development, and the specific tumor antigen target has not been publicly disclosed.

Other names

iPSC-derived CAR-T cell therapyinduced pluripotent stem cell-derived chimeric antigen receptor T cell therapy